Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Gabriel Valley Index
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
ZyVersa Therapeutics, Inc. - Common Stock
(NQ:
ZVSA
)
2.820
-0.200 (-6.62%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
185,140
Open
3.210
Bid (Size)
2.780 (2)
Ask (Size)
2.900 (6)
Prev. Close
3.020
Today's Range
2.780 - 3.249
52wk Range
2.610 - 79.80
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024
August 09, 2024
ZVSA stock results show that ZyVersa Therapeutics beat analyst estimates for earnings per share the second quarter of 2024.
Via
InvestorPlace
ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update
August 09, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Performance
YTD
-67.95%
-67.95%
1 Month
-35.62%
-35.62%
3 Month
-41.98%
-41.98%
6 Month
-51.11%
-51.11%
1 Year
-94.96%
-94.96%
More News
Read More
ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation
August 07, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults
July 29, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Peering Into ZyVersa Therapeutics's Recent Short Interest
May 21, 2024
Via
Benzinga
ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100
July 25, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model
July 18, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
SmallCap Tech/Biotech Stocks July/Aug 2024: ZVSA, DYAI, ZVRA, PRSO, RLMD, VTAK, ENTO, INBS, KAVL
July 11, 2024
Via
AB Newswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024
July 09, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024
May 15, 2024
Via
InvestorPlace
ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update
May 15, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention
May 14, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Why Clever Leaves Holdings Shares Are Trading Lower By Around 60%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 29, 2024
Via
Benzinga
What's Going On With ZyVersa Stock?
April 29, 2024
Via
Benzinga
ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer’s Disease
April 29, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Why Aon Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
April 26, 2024
Via
Benzinga
ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes
April 04, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update
March 25, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Benzinga's 2024 Virtual Healthcare: What's Next In Health?
March 19, 2024
Via
Benzinga
ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator™ VAR 200 in Patients with Diabetic Kidney Disease
March 18, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled “Inflammation Illuminated,”at Benzinga’s Virtual Healthcare Summit 2024 on March 20, 2024
March 14, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
12 Health Care Stocks Moving In Thursday's Intraday Session
March 07, 2024
Via
Benzinga
ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity
February 29, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100’s Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications
February 28, 2024
From
ZyVersa Therapeutics
Via
GlobeNewswire
Why TransMedics Group Shares Are Trading Higher By Around 23%; Here Are 20 Stocks Moving Premarket
February 27, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.